• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

FASEB J . The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation

tetano

Editor, Senior Moderator
FASEB J


. 2020 Jun 17.
doi: 10.1096/fj.202001020R. Online ahead of print.
The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation


Junyi Wang[SUP] 1 2 [/SUP], Nihal Kaplan[SUP] 2 [/SUP], Jan Wysocki[SUP] 3 [/SUP], Wending Yang[SUP] 2 [/SUP], Kurt Lu[SUP] 2 [/SUP], Han Peng[SUP] 2 [/SUP], Daniel Batlle[SUP] 3 [/SUP], Robert M Lavker[SUP] 2 [/SUP]



Affiliations

Abstract

Angiotensin converting enzyme 2 (ACE2) plays an important role in inflammation, which is attributable at least, in part, to the conversion of the pro-inflammatory angiotensin (Ang) II peptide into angiotensin 1-7 (Ang 1-7), a peptide which opposes the actions of AngII. ACE2 and AngII are present in many tissues but information on the cornea is lacking. We observed that mice deficient in the Ace2 gene (Ace2[SUP]-/-[/SUP]), developed a cloudy cornea phenotype as they aged. Haze occupied the central cornea, accompanied by corneal edema and neovascularization. In severe cases with marked chronic inflammation, a cell-fate switch from a transparent corneal epithelium to a keratinized, stratified squamous, psoriasiform-like epidermis was observed. The stroma contained a large number of CD11c, CD68, and CD3 positive cells. Corneal epithelial debridement experiments in young ACE2-deficient mice showed normal appearing corneas, devoid of haze. We hypothesized, however, that these mice are "primed" for a corneal inflammatory response, which once initiated, would persist. In vitro studies reveal that interleukins (IL-1a, IL-1b), chemokines (CCL2, CXCL8), and TNF-α, are all significantly elevated, resulting in a cytokine storm-like phenotype. This phenotype could be partially rescued by treatment with the AngII type 1 receptor (AT1R) antagonist, losartan, suggesting that the observed effect was mediated by AngII acting on its main receptor. Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes human ACE2 as the receptor for entry with subsequent downregulation of ACE2, corneal inflammation in Ace2[SUP]-/-[/SUP] mice may have a similar mechanism with that in COVID-19 patients. Thus the Ace2[SUP]-/-[/SUP] cornea, because of easy accessibility, may provide an attractive model to explore the molecular mechanisms, immunological changes, and treatment modalities in patients with COVID-19.

Keywords: COVID‐19; SARS‐CoV‐2; cornea; corneal epithelial cells; macrophages.
 
Back
Top Bottom